Evidence map›Paper›PMID 31439615›Full record

ArticleCancer immunology research2019

Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs.

Charles S Tannenbaum, Patricia A Rayman, Paul G Pavicic, Jin Sub Kim, Wei Wei, Alexandra Polefko, Wesley Wallace, Brian I Rini, Gareth Morris-Stiff, Daniela S Allende and 3 more

Abstract read
In one paragraph

Article in Cancer immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 59 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. The Significance of CXCL1 in Cancer: An Overview of Molecular Mechanisms.International journal of molecular sciences · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Charles S TannenbaumDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Patricia A RaymanDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Paul G PavicicDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Jin Sub KimDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Wei WeiTaussig Cancer Center, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-0960-7269
Alexandra PolefkoDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Wesley WallaceDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Brian I RiniTaussig Cancer Center, Cleveland Clinic, Cleveland, Ohio.
Gareth Morris-StiffDepartment of General Surgery, Cleveland Clinic, Cleveland, Ohio.
Daniela S AllendeDepartment of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio.
Thomas HamiltonDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-9817-242X
James H FinkeDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
C Marcela Diaz-MonteroDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. diazc2@ccf.org.ORCID 0000-0002-6941-4215
Cleveland Clinic Lerner College of Medicine · USCleveland Clinic · US

Funding

Regulation of MDSC function and traffickingR01CA168488 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI FINKE, JAMES H · 2013 to 2017
$1.9M
Programming T Cells for Successful Adoptive Cell TherapyK01CA134927 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI DIAZ-MONTERO, CLAUDIA MARCELA · 2009 to 2013
$645k
Improving adoptive cell therapy by enhancing T cell longevityR21CA188767 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI DIAZ-MONTERO, CLAUDIA MARCELA · 2015 to 2016
$379k
NCI NIH HHS K01 CA134927NCI NIH HHS R01 CA168488NCI NIH HHS R21 CA188767
6 · The paper itself

Abstract

Myeloid-derived suppressor cells (MDSC) are induced by and accumulate within many histologically distinct solid tumors, where they promote disease by secreting angiogenic and immunosuppressive molecules. Although IL1β can drive the generation, accumulation, and functional capacity of MDSCs, the specific IL1β-induced inflammatory mediators contributing to these activities remain incompletely defined. Here, we identified IL1β-induced molecules that expand, mobilize, and modulate the accumulation and angiogenic and immunosuppressive potencies of polymorphonuclear (PMN)-MDSCs. Unlike parental CT26 tumors, which recruited primarily monocytic (M)-MDSCs by constitutively expressing GM-CSF- and CCR2-directed chemokines, IL1β-transfected CT26 produced higher G-CSF, multiple CXC chemokines, and vascular adhesion molecules required for mediating infiltration of PMN-MDSCs with increased angiogenic and immunosuppressive properties. Conversely, CT26 tumors transfected with IL1β-inducible molecules could mobilize PMN-MDSCs, but because they lacked the ability to upregulate IL1β-inducible CXCR2-directed chemokines or vascular adhesion molecules, additional PMN-MDSCs could not infiltrate tumors. IL1β-expressing CT26 increased angiogenic and immunosuppressive factors of tumor-infiltrating MDSCs, as did CT26 tumors individually transfected with G-CSF, Bv8, CXCL1, or CXCL5, demonstrating that mediators downstream of IL1β could also modulate MDSC functional activity. Translational relevance was indicated by the finding that the same growth factors, cytokines, chemokines, and adhesion molecules responsible for the mobilization and recruitment of PMN-MDSCs into inflammatory CT26 murine tumors were also coordinately upregulated with increasing IL1β expression in human renal cell carcinoma tumors. These studies demonstrated that IL1β stimulated the components of a multifaceted inflammatory program that produces, mobilizes, chemoattracts, activates, and mediates the infiltration of PMN-MDSCs into inflammatory tumors to promote tumor progression.

Indexed as

InflammationAnimalsCarcinoma, Renal CellCell Line, TumorChemokine CXCL1ChemokinesDisease Models, AnimalFemaleGene Expression ProfilingHumansInterleukin-1betaKidney NeoplasmsMiceMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutChemokine CXCL1ChemokinesCXCL1 protein, humanIL1B protein, humanIL1B protein, mouseInterleukin-1betapoliovirus receptorReceptors, Virus

Identifiers

PMID31439615
PMCPMC6774821
OpenAlexW2969505681

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.